Navigation Links
Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C

on PROVE 2 data, regimens that may exclude RBV. Vertex expects to focus on treatment durations of no more than 24 weeks. Vertex and Tibotec are planning to meet with regulatory authorities to discuss the Phase 3 design in mid-2007 and are planning to initiate Phase 3 clinical development in the fourth quarter of 2007. The registration strategy and timing of an NDA filing will be dependent on discussions with regulatory authorities.

PROVE 1 Results at EASL

Interim 12-week antiviral analysis of PROVE 1

A total of 250 patients were enrolled in PROVE 1 and received at least one dose of telaprevir or placebo in addition to Peg-interferon alfa-2a (peg-IFN) + ribavirin (RBV) in the study. A total of 175 patients received at least one dose of telaprevir in 1 of 3 arms (treatment arms B, C and D) and 75 patients received at least one dose of placebo (arm A). Treatment with telaprevir resulted in a high proportion of patients achieving a rapid viral response at 4 weeks. At the time of the interim analysis, all patients had either completed 12 weeks or discontinued from the study prior to week 12. Available 4-week and 12-week results are detailed in the following table: -0-

 Interim HCV RNA results for Patients Enrolled in the PROVE 1 Trial

---------------------------------------------------------------------

Treatment Assignment            Patients Patients Patients Patients

                                 with     with     with     with HCV

                                 HCV RNA  HCV RNA  HCV RNA  RNA (less

                                 (less    (less    (less    than)10

                                 than)30  than)10  than)10  IU/mL at

                                 IU/mL    IU/mL    IU/mL    end of 12

                                 at end   at end   at end   weeks of

                                 of 4     of 4     of 12    dosing

                                 weeks    weeks    weeks    (last on-

                 
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
(Date:7/10/2014)... , July 10, 2014  The U.S. Department ... three-year grant to University Hospitals (UH) Case Medical Center ... new national model aimed at improving care for patients ... Care," the project will test a unique model developed ... with late-stage disease, significant comorbidities, or demonstrated need for ...
(Date:7/10/2014)...  RESMED INC. (NYSE: RMD ) today announced ... ended June 30, 2014 results on Thursday, July 31, 2014, ... release with ResMed,s results will be issued after 1:00 p.m. ... to discuss operating results and future outlook. The ... Pacific Time and the live webcast of the call can ...
(Date:7/10/2014)... July 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... it has completed the sale to Galderma of all ... or held by Valeant for $1.4 billion in cash, ... which recently completed its acquisition of Galderma. ... our products to a company that is firmly committed ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
(Date:7/10/2014)... July 10, 2014 Ticketability.com has a wide ... now Paul McCartney tickets for San Diego are being added ... Diego since 1976, and the newly added September 28 show ... , Click Here to view the selection of ... Petco Park will become available to the general public on ...
(Date:7/10/2014)... D.C. (PRWEB) July 10, 2014 One ... for Bangladesh Worker Safety announced today it will extend ... to four months’ wages for workers displaced as a ... To date, Alliance inspections have resulted in the closure ... in all five cases, raising immediate safety concerns. In ...
(Date:7/10/2014)... 2014 According to a new ... Platforms (Land, Airborne, Naval), Application (Software Defined Radios, ... Geography (North America, Asia-Pacific, Europe, the Middle East ... by MarketsandMarkets, the market is estimated to be ... register a CAGR of 5.56% to reach $39.52 ...
(Date:7/10/2014)... In his latest blog post at http://www.perwickstrom.com , ... Wickstrom has listed 5 ways to follow-up without being ... get information or sometimes even just return an inquiry, ... a skill that most people don’t have,” commented Per ... dialogue moving without coming across as annoying – let ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 A ... program that gets clients off to a great start ... can believe in, has launched a new Eating Disorders ... The new section highlights:, , Different ... Statistic Manual of Mental Disorders (DSM-IV), including anorexia nervosa, ...
Breaking Medicine News(10 mins):Health News:Paul McCartney Tickets for San Diego: Ticketability.com Announces Discounted Tickets for McCartney’s Tour Stop at Petco Park on September 28 2Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Per Wickstrom’s Latest Blog Post Lists 5 Ways to Follow-up Without Being Annoying 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2
... May 15 Gerson Lehrman Group, the world,s,leading ... a Web-based community devoted to providing patients with ... own healthcare.,iGuard.org provides personalized iGuard Risk Ratings, iGuard ... their experience with other registered,users who also want ...
... of healthcare and medical device experience to board ... of fast-growing ... the first and only flexible CO2 laser scalpel enabling new procedures ... to the company,s board of directors. Suennen, co-founder and,managing member of ...
... /Xinhua-PRNewswire/ -- Tiens Biotech Group (USA), Inc.,(the ,Company, or ,Tiens,), ... for the first quarter ended March 31, 2008., Revenue ... to,$16.2 million for the first quarter of 2007., Net ... or $0.05 per,share, compared to net income of $6.5 million, ...
... a Cranergy(TM) ... Fuel Station in NYC,s Penn Station, LAKEVILLE-MIDDLEBORO, Mass., May ... country and lift people from,America,s other energy crisis. With hectic, ... at multi-tasking, most,people need an extra boost to keep them ...
... of altruism; helping others ... one,s own health issues, CHICAGO, May 15 Meet Cindy Zamirowski, ... "cancer,free" thumbs up from her physician, stepped off the curb to raise ... The Bolingbrook mom of three and grandma of three rallied her ...
... DURHAM, N.C. -- By targeting and disabling a protein frequently ... the cancer more vulnerable to chemotherapy, according to a new ... We tested a compound that can weaken the tumor by ... cell. When chemotherapy was applied to the tumor in this ...
Cached Medicine News:Health News:Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions 2Health News:Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions 3Health News:Lisa M. Suennen Joins OmniGuide(R) Board of Directors 2Health News:Tiens Biotech Group (USA) Reports First Quarter Results 2Health News:Tiens Biotech Group (USA) Reports First Quarter Results 3Health News:Tiens Biotech Group (USA) Reports First Quarter Results 4Health News:Tiens Biotech Group (USA) Reports First Quarter Results 5Health News:Tiens Biotech Group (USA) Reports First Quarter Results 6Health News:Tiens Biotech Group (USA) Reports First Quarter Results 7Health News:Tiens Biotech Group (USA) Reports First Quarter Results 8Health News:Tiens Biotech Group (USA) Reports First Quarter Results 9Health News:Tiens Biotech Group (USA) Reports First Quarter Results 10Health News:Tiens Biotech Group (USA) Reports First Quarter Results 11Health News:Video: Ocean Spray Revitalizes Americans Naturally With Free Fuel for Their Bodies 2Health News:After Effects: Giving Back Is Good for You 2Health News:Targeted therapy plus chemotherapy may pack 1-2 punch against melanoma 2
... helps you deliver unmatched performance through patient-focused ... the most complete anesthesia solution developed, putting ... - at your fingertips., ,The Aisys ... legacy of anesthesia delivery and patient monitoring ...
... Premilene Mesh LP Self-Forming Plug is combining ... This results in a very soft hernia plug ... to standard Plugs less foreign body material is ... the hernia size and shape allows for a ...
... Celsius Control System provides physicians,with ... safely,and rapidly lower patient body ... temperature and,rewarm patients to normothermic ... consists of an endovascular,catheter, console ...
... Fiberoptics Gemini surgical headlight is perfectly balanced ... durable and ultra-low-profile and illuminates brilliantly while ... annoying "rams effect." The fully adjustable headband, ... to sit low on the brow, directing ...
Medicine Products: